Benzinga | Jan 10, 2022 08:06AM EST

Agile Therapeutics, Afaxys Report Partnership To Expand Access To Twirla Transdermal System, No Terms Disclosed

Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced a new alliance with Afaxys Pharma, LLC to promote Twirla(r) (levonorgestrel and ethinyl estradiol) transdermal system.



Every year, more than 31 million Americans rely on community and public health centers to get essential care. This agreement expands access of Twirla in the U.S. family planning community and for the patients who rely on healthcare in this setting. As a trusted expert in community and public health, Afaxys is a leading provider of innovative contraceptive options, which will now include Twirla, an effective, low-dose contraceptive option in a non-daily, non-invasive patch.

"Afaxys and Agile Therapeutics are aligned on a mutual goal to provide reliable, affordable contraceptive access to women on their sexual and reproductive health journeys," said Ronda Dean, President, CEO & Co-Founder of Afaxys. "We are committed to community and public health patients and providers, and this alliance will empower women with one more reliable family planning option to consider as they work with their physicians to choose the method of contraception that is right for them."

"This strategic agreement with Afaxys, a recognized leader in the public health system, will help ensure that Twirla is available, accessible and affordable to a much broader group of patients who can benefit from it," commented Al Altomari, Chairman and CEO of Agile Therapeutics. "We look forward to advancing women's reproductive health together."